Poliomyelitis

Virus

Non-enveloped ssRNA(+), Picornaviridae, genus Enterovirus. 3 SEROTYPES (1,2,3), NO cross-protection → vaccines must cover all 3.

Transmission/Pathogenesis

Fecal-oral → initial replication oropharynx + gut-associated lymphoid tissue. MOST infections asymptomatic/minor (key epi point) — small minority → viremia → smaller subset → CNS invasion. CNS tropism: ANTERIOR HORN motor neurons (spinal) ± brainstem motor nuclei (bulbar) — selective MOTOR destruction = basis for defining clinical feature.

Clinical

Majority: asymptomatic/mild febrile illness, NO neuro involvement (public perception ≠ typical course). Paralytic poliomyelitis (small minority): ACUTE FLACCID PARALYSIS — ASYMMETRIC, MOTOR ONLY (no sensory loss — reflects pure anterior horn tropism, key contrast vs other flaccid paralysis causes with sensory involvement). Legs classically more affected. Bulbar polio: brainstem motor nuclei → swallowing difficulty + RESPIRATORY MUSCLE PARALYSIS (historic “iron lung” era) — most life-threatening form. Partial recovery possible over weeks-months; residual permanent weakness common in paralytic survivors.

Post-Polio Syndrome (delayed sequela, testable)

DECADES after acute illness: new weakness/fatigue/pain in previously (or occasionally un-)affected muscles. Mechanism: functional decline of overworked COMPENSATORY motor units, NOT viral reactivation/reinfection. Distinctive example of delayed neuro sequela in curriculum.

Diagnosis

Viral culture: STOOL = highest yield (ongoing shedding) > throat swab/CSF. RT-PCR: rapid + STRAIN DIFFERENTIATION (wild-type vs vaccine-derived) — key for eradication surveillance.

Eradication/Vaccines (defining public health angle)

Global Polio Eradication Initiative: >99% case reduction since late 1980s. Wild serotypes 2+3 CERTIFIED ERADICATED; serotype 1 endemic in few countries only.

OPV (oral, live-attenuated): strong MUCOSAL/intestinal immunity → blocks TRANSMISSION, primary tool for outbreak control/eradication. Risk: vaccine-derived poliovirus (VDPV) — reversion to neurovirulence in under-immunized population circulation → vaccine-associated paralytic poliomyelitis (VAPP), small but real. IPV (injectable, inactivated): NO live-virus/reversion risk → used in polio-free high-income countries. WEAKER mucosal immunity — protects individual, less effective blocking community transmission than OPV.

OPV vs IPV trade-off = high-yield testable comparison: transmission-blocking+reversion-risk vs safer+less-transmission-blocking.

The Virus

Poliovirus is a non-enveloped, single-stranded positive-sense RNA virus of the Picornaviridae family (genus Enterovirus), existing as three distinct serotypes (1, 2, and 3, with no meaningful cross-protection between them, which is precisely why comprehensive vaccines must cover all three) — its picornavirus family membership places it alongside several other enteric/respiratory viruses covered elsewhere in this curriculum, sharing the family’s general small, non-enveloped, faecal-orally-transmissible structural pattern.

Transmission and Pathogenesis

Transmission is predominantly faecal-oral, with the virus initially replicating in the oropharynx and gut-associated lymphoid tissue after ingestion — the large majority of infections (a genuinely important, specifically testable epidemiological point) remain entirely asymptomatic or minor/nonspecific, with only a small minority progressing beyond this initial gut/lymphoid replication to viraemia and, in a genuinely small further subset, CNS invasion. When CNS invasion does occur, the virus shows a specific, defining tropism for anterior horn motor neurons of the spinal cord (and, less commonly, brainstem motor nuclei in bulbar poliomyelitis) — this selective destruction of motor, rather than sensory, neurons is the direct anatomical basis for poliomyelitis’s defining clinical feature below.

Clinical Manifestations

The overwhelming majority of infections are asymptomatic or present as a mild, nonspecific febrile illness that resolves without any neurological involvement — genuinely important to remember given how the disease’s public perception (paralysis) doesn’t reflect its actual typical clinical course. In the small minority progressing to paralytic poliomyelitis, the defining, specifically testable clinical signature is acute flaccid paralysis that is characteristically asymmetric, affects motor function only (no sensory loss — directly reflecting the anterior-horn-specific, purely motor neuron tropism above, and a genuinely important, specifically testable point of contrast with other causes of flaccid paralysis where sensory involvement helps distinguish aetiology), and can affect any limb, though the legs are classically more commonly involved. Bulbar poliomyelitis, from brainstem motor nuclei involvement, is a more severe, less common variant causing difficulty swallowing and, critically, potential respiratory muscle paralysis — historically the reason for mechanical ventilatory support devices (“iron lungs”) in the pre-vaccine era, and still today the most immediately life-threatening presentation. Paralysis, where it occurs, may partially recover over subsequent weeks to months, but residual, permanent weakness in affected muscle groups is common in surviving paralytic cases.

Post-Polio Syndrome — A Genuinely Delayed Sequela

A genuinely important, specifically testable long-term point: some individuals who recovered from paralytic poliomyelitis, often decades after the original acute illness, develop post-polio syndrome — new-onset weakness, fatigue, and pain in previously affected (or occasionally unaffected) muscle groups, thought to reflect the eventual functional decline/exhaustion of compensatory motor units that had been overworking to sustain function in surviving, previously affected muscles since the original illness — a real, distinctive example in this curriculum of a viral infection’s neurological consequences resurfacing many years after apparent full recovery, distinct from ongoing viral activity (post-polio syndrome is not a reactivation or reinfection).

Diagnosis

Viral isolation/culture from stool (the highest-yield specimen, reflecting ongoing gut replication and faecal shedding even after the acute illness) or, less reliably, throat swab or CSF, remains a key diagnostic approach, with RT-PCR increasingly used for more rapid, sensitive detection and, importantly, for strain differentiation — distinguishing wild-type poliovirus from vaccine-derived strains, a genuinely important distinction for global eradication surveillance (below).

Global Eradication and Vaccination — The Genuinely Defining Public Health Story

Poliomyelitis is the subject of one of global public health’s most ambitious ongoing efforts: the Global Polio Eradication Initiative, which has reduced wild poliovirus cases by over 99% since the late 1980s, with wild-type serotypes 2 and 3 now certified eradicated globally and serotype 1 remaining endemic only in a small number of countries — a genuinely important context point for understanding why polio, unlike most infections in this curriculum, is discussed as much through a public-health/eradication lens as a clinical one. Two vaccine types exist, each with genuinely important, specifically testable trade-offs: the oral polio vaccine (OPV), a live-attenuated vaccine given orally, induces strong mucosal/intestinal immunity (blocking transmission, not just disease, which is precisely why it has been the primary tool for outbreak control and eradication campaigns) but carries a small, genuinely real risk of vaccine-derived poliovirus (VDPV) — reversion of the attenuated strain toward neurovirulence during prolonged circulation in under-immunized populations, occasionally causing vaccine-associated paralytic poliomyelitis (VAPP); and the inactivated polio vaccine (IPV), given by injection, carries no live-virus/reversion risk at all (making it the only vaccine used in most high-income, polio-free countries) but induces comparatively weaker mucosal immunity, meaning it protects the individual from paralytic disease effectively but is less effective at interrupting community transmission than OPV — this OPV-versus-IPV trade-off (transmission-blocking mucosal immunity with a small reversion risk, versus safer but less transmission-blocking injectable immunity) is genuinely one of the most specifically testable vaccine-strategy comparisons in the entire curriculum.